Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
ORGANIZATION
FPMAJ Renews Call to Ensure Stable Supply System to Prep for COVID Outbreak
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) on July 23 renewed its calls on its member organizations and companies to ensure stable drug supply systems in preparation for a potential spike in COVID-19 cases later this summer. The…
To read the full story
Related Article
ORGANIZATION
- Rethink Labor Cost Calculations in Drug Pricing: Pharma Labor Group
November 5, 2026
- Medipal’s Choufuku Takes Over as JPWA Vice Chair
November 4, 2026
- Enhertu, Dupixent Win 2026 International Prix Galien Biotechnology Award
November 2, 2026
- Pharma Trade Groups Flag Potential Leak of 30,000 Email Addresses
November 2, 2026
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…